Hint mode is switched on Switch off
For swift navigation between sections

Protalix Biotherapeutics
LEI 549300SDVB3GP4XDFM60

PDF download

Choose all Reset all
Download Cancel
Organization name
Protalix Biotherapeutics Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Protalix BioTherapeutics is pharmaceutical company whose plant-based enzyme, taliglucerase alfa, has been approved by the U.S. Food and Drug Administration for the treatment of Gaucher disease.

Awards

News

11/02/2026 Protalix Biotherapeutics: To This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing, Financial Statements And Exhibits
13/11/2025 Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
17/10/2025 Protalix Biotherapeutics: To This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing, Other Events, Financial Statements And Exhibits
21/07/2025 Protalix Biotherapeutics: Is Incorporated Herein By Reference, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
07/11/2024 Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300SDVB3GP4XDFM60
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001006281
  • EIN
    65-0643773
Registration is required to get access.